JP2000508310A - α▲下1▼―交感神経受容体拮抗薬 - Google Patents
α▲下1▼―交感神経受容体拮抗薬Info
- Publication number
- JP2000508310A JP2000508310A JP9535919A JP53591997A JP2000508310A JP 2000508310 A JP2000508310 A JP 2000508310A JP 9535919 A JP9535919 A JP 9535919A JP 53591997 A JP53591997 A JP 53591997A JP 2000508310 A JP2000508310 A JP 2000508310A
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- aryl
- compound
- hydrogen
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940044551 receptor antagonist Drugs 0.000 title description 2
- 239000002464 receptor antagonist Substances 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 71
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims description 178
- 150000001875 compounds Chemical class 0.000 claims description 144
- -1 2,5-dimethylphenyl Chemical group 0.000 claims description 103
- 229910052739 hydrogen Inorganic materials 0.000 claims description 75
- 239000001257 hydrogen Substances 0.000 claims description 75
- 125000003118 aryl group Chemical group 0.000 claims description 58
- 150000002431 hydrogen Chemical class 0.000 claims description 46
- 125000000623 heterocyclic group Chemical group 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 230000008602 contraction Effects 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 208000007232 portal hypertension Diseases 0.000 claims description 22
- 210000003240 portal vein Anatomy 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 230000007882 cirrhosis Effects 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 150000001721 carbon Chemical group 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 241000700159 Rattus Species 0.000 claims description 9
- 230000001629 suppression Effects 0.000 claims description 9
- 210000000709 aorta Anatomy 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000002889 sympathetic effect Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 210000003752 saphenous vein Anatomy 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 abstract description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 abstract 1
- 238000002844 melting Methods 0.000 description 73
- 230000008018 melting Effects 0.000 description 73
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 68
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 61
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 55
- 238000000921 elemental analysis Methods 0.000 description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- 239000000543 intermediate Substances 0.000 description 44
- 238000012360 testing method Methods 0.000 description 37
- WBJWXIQDBDZMAW-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carbonyl chloride Chemical compound C1=CC=CC2=C(C(Cl)=O)C(O)=CC=C21 WBJWXIQDBDZMAW-UHFFFAOYSA-N 0.000 description 36
- PYHXGXCGESYPCW-UHFFFAOYSA-N alpha-phenylbenzeneacetic acid Natural products C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 31
- 239000002253 acid Substances 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- 229960004132 diethyl ether Drugs 0.000 description 20
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 20
- 229960001802 phenylephrine Drugs 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 19
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
- 230000009989 contractile response Effects 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- JRGGUPZKKTVKOV-UHFFFAOYSA-N 1-bromo-3-chlorobenzene Chemical compound ClC1=CC=CC(Br)=C1 JRGGUPZKKTVKOV-UHFFFAOYSA-N 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- GZQVHUHROSRCQF-UHFFFAOYSA-N ethyl 2-(3-chlorophenyl)-2-hydroxypropanoate Chemical compound CCOC(=O)C(C)(O)C1=CC=CC(Cl)=C1 GZQVHUHROSRCQF-UHFFFAOYSA-N 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 150000004682 monohydrates Chemical class 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000012047 saturated solution Substances 0.000 description 7
- 230000008313 sensitization Effects 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000000052 vinegar Substances 0.000 description 6
- 235000021419 vinegar Nutrition 0.000 description 6
- JIWHIRLNKIUYSM-UHFFFAOYSA-N 1-(3-methylphenyl)piperazine Chemical compound CC1=CC=CC(N2CCNCC2)=C1 JIWHIRLNKIUYSM-UHFFFAOYSA-N 0.000 description 5
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012156 elution solvent Substances 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 238000012417 linear regression Methods 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 4
- 229960001289 prazosin Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 3
- GASZMNCYHARHHI-UHFFFAOYSA-N 2-hydroxy-2-naphthalen-1-ylpropanoic acid Chemical compound C1=CC=C2C(C(O)(C(O)=O)C)=CC=CC2=C1 GASZMNCYHARHHI-UHFFFAOYSA-N 0.000 description 3
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 3
- YNAXOXAOWFZWCZ-UHFFFAOYSA-N 3-(benzylamino)-2-methyl-3-oxo-2-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(O)=O)(C)C(=O)NCC1=CC=CC=C1 YNAXOXAOWFZWCZ-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 241000283977 Oryctolagus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 3
- 229960004484 carbachol Drugs 0.000 description 3
- 150000003857 carboxamides Chemical class 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000006264 debenzylation reaction Methods 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000004701 malic acid derivatives Chemical class 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 229950009195 phenylpropanol Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical group C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- WICKLEOONJPMEQ-UHFFFAOYSA-N 1-(2-methylphenyl)piperazine Chemical compound CC1=CC=CC=C1N1CCNCC1 WICKLEOONJPMEQ-UHFFFAOYSA-N 0.000 description 2
- SAWFUBGUJCDRNJ-UHFFFAOYSA-N 1-(2-piperazin-1-ylphenyl)propan-1-ol Chemical compound CCC(O)C1=CC=CC=C1N1CCNCC1 SAWFUBGUJCDRNJ-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- ZVBNSAWGGIBBJY-UHFFFAOYSA-N 2-(2-chlorophenyl)-2-hydroxypropanenitrile Chemical compound N#CC(O)(C)C1=CC=CC=C1Cl ZVBNSAWGGIBBJY-UHFFFAOYSA-N 0.000 description 2
- CBCWYSYBRINEON-UHFFFAOYSA-N 2-(methanesulfonamido)-2-phenylacetic acid Chemical compound CS(=O)(=O)NC(C(O)=O)C1=CC=CC=C1 CBCWYSYBRINEON-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- VOCFIOFIJYGAKY-UHFFFAOYSA-N 2-hydroxy-2-phenylhexanoic acid Chemical compound CCCCC(O)(C(O)=O)C1=CC=CC=C1 VOCFIOFIJYGAKY-UHFFFAOYSA-N 0.000 description 2
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
- YNNIOBNUNOYVLD-UHFFFAOYSA-N 2-phenyl-2-[(2-phenylacetyl)amino]acetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)NC(=O)CC1=CC=CC=C1 YNNIOBNUNOYVLD-UHFFFAOYSA-N 0.000 description 2
- BPINPOKMMPFERY-UHFFFAOYSA-N 3-(6-hydroxy-4-methoxy-6-methylcyclohexa-2,4-dien-1-yl)propanenitrile Chemical compound COC1=CC(C)(O)C(CCC#N)C=C1 BPINPOKMMPFERY-UHFFFAOYSA-N 0.000 description 2
- BGPVBLLISJEHPY-UHFFFAOYSA-N 3-(benzylamino)-3-oxo-2-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(=O)NCC1=CC=CC=C1 BGPVBLLISJEHPY-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- QSBAHMROFICXDC-UHFFFAOYSA-N 3-oxo-2-phenyl-3-phenylmethoxypropanoic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C(=O)OCC1=CC=CC=C1 QSBAHMROFICXDC-UHFFFAOYSA-N 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical group BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- KGUIOHXCGVQYEG-UHFFFAOYSA-N diethyl 2-methyl-2-phenylpropanedioate Chemical compound CCOC(=O)C(C)(C(=O)OCC)C1=CC=CC=C1 KGUIOHXCGVQYEG-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- ZAMAQXKCHHTBDB-UHFFFAOYSA-N ethyl 2-hydroxy-2-(3-phenylphenyl)propanoate Chemical compound C(C)OC(C(C=1C=C(C=CC1)C1=CC=CC=C1)(C)O)=O ZAMAQXKCHHTBDB-UHFFFAOYSA-N 0.000 description 2
- OKSROYSIBCGJDM-UHFFFAOYSA-N ethyl 2-hydroxy-2-(4-methoxyphenyl)propanoate Chemical compound CCOC(=O)C(C)(O)C1=CC=C(OC)C=C1 OKSROYSIBCGJDM-UHFFFAOYSA-N 0.000 description 2
- CIOPBIWRODURAV-UHFFFAOYSA-N ethyl 2-hydroxy-2-(4-methylphenyl)propanoate Chemical compound CCOC(=O)C(C)(O)C1=CC=C(C)C=C1 CIOPBIWRODURAV-UHFFFAOYSA-N 0.000 description 2
- FBYUEYAEBRPFCT-UHFFFAOYSA-N ethyl 2-hydroxy-2-naphthalen-1-ylpropanoate Chemical compound C1=CC=C2C(C(C)(O)C(=O)OCC)=CC=CC2=C1 FBYUEYAEBRPFCT-UHFFFAOYSA-N 0.000 description 2
- UNYKSRMYGYLUBF-UHFFFAOYSA-N ethyl 2-hydroxy-2-naphthalen-2-ylpropanoate Chemical compound C1=CC=CC2=CC(C(C)(O)C(=O)OCC)=CC=C21 UNYKSRMYGYLUBF-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 229910001623 magnesium bromide Inorganic materials 0.000 description 2
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 2
- DOGRFNDQFDHDNY-UHFFFAOYSA-N n-(3-hydroxypropyl)-2,2-diphenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)NCCCO)C1=CC=CC=C1 DOGRFNDQFDHDNY-UHFFFAOYSA-N 0.000 description 2
- NHKOTMXNWYRLPZ-UHFFFAOYSA-N n-(3-iodopropyl)-2,2-diphenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)NCCCI)C1=CC=CC=C1 NHKOTMXNWYRLPZ-UHFFFAOYSA-N 0.000 description 2
- XXFIOQLDBDLESX-UHFFFAOYSA-N n-(3-iodopropyl)-n-methyl-2,2-diphenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N(CCCI)C)C1=CC=CC=C1 XXFIOQLDBDLESX-UHFFFAOYSA-N 0.000 description 2
- OBNCPLMOSANILN-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-n-methyl-2,2-diphenylacetamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)C(=O)N(C)CCCN(CC1)CCN1C1=CC(C)=CC=C1C OBNCPLMOSANILN-UHFFFAOYSA-N 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical compound OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- HAFWELDDNUXLCK-TYYBGVCCSA-N (e)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C\C(O)=O HAFWELDDNUXLCK-TYYBGVCCSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YRIFWVMRUFKWLM-UHFFFAOYSA-N 1-(2,5-dimethylphenyl)piperazine Chemical compound CC1=CC=C(C)C(N2CCNCC2)=C1 YRIFWVMRUFKWLM-UHFFFAOYSA-N 0.000 description 1
- PWZDJIUQHUGFRJ-UHFFFAOYSA-N 1-(2-chlorophenyl)piperazine Chemical compound ClC1=CC=CC=C1N1CCNCC1 PWZDJIUQHUGFRJ-UHFFFAOYSA-N 0.000 description 1
- FBQIUSDQWOLCNY-UHFFFAOYSA-N 1-(2-ethoxyphenyl)piperazine Chemical compound CCOC1=CC=CC=C1N1CCNCC1 FBQIUSDQWOLCNY-UHFFFAOYSA-N 0.000 description 1
- BFOWAUXYQBEQGF-UHFFFAOYSA-N 1-(2-prop-1-enylphenyl)piperazine Chemical compound CC=CC1=CC=CC=C1N1CCNCC1 BFOWAUXYQBEQGF-UHFFFAOYSA-N 0.000 description 1
- ONEYFZXGNFNRJH-UHFFFAOYSA-N 1-(4-methylphenyl)piperazine Chemical compound C1=CC(C)=CC=C1N1CCNCC1 ONEYFZXGNFNRJH-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- QBELEDRHMPMKHP-UHFFFAOYSA-N 1-bromo-2-chlorobenzene Chemical compound ClC1=CC=CC=C1Br QBELEDRHMPMKHP-UHFFFAOYSA-N 0.000 description 1
- USYQKCQEVBFJRP-UHFFFAOYSA-N 1-bromo-3-phenylbenzene Chemical group BrC1=CC=CC(C=2C=CC=CC=2)=C1 USYQKCQEVBFJRP-UHFFFAOYSA-N 0.000 description 1
- ZBTMRBYMKUEVEU-UHFFFAOYSA-N 1-bromo-4-methylbenzene Chemical compound CC1=CC=C(Br)C=C1 ZBTMRBYMKUEVEU-UHFFFAOYSA-N 0.000 description 1
- DLKQHBOKULLWDQ-UHFFFAOYSA-N 1-bromonaphthalene Chemical compound C1=CC=C2C(Br)=CC=CC2=C1 DLKQHBOKULLWDQ-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N 1-propanol Substances CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- ZEXPENITPLXFLY-UHFFFAOYSA-N 2-(2-chlorophenyl)-2-hydroxypropanoic acid Chemical compound OC(=O)C(O)(C)C1=CC=CC=C1Cl ZEXPENITPLXFLY-UHFFFAOYSA-N 0.000 description 1
- XLXRCJUQYMSVBT-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-hydroxypropanamide Chemical compound CC1=CC=C(C)C(N2CCN(CCCNC(=O)C(C)(O)C=3C(=CC=CC=3)Cl)CC2)=C1 XLXRCJUQYMSVBT-UHFFFAOYSA-N 0.000 description 1
- MUUPOSALJOLPHK-UHFFFAOYSA-N 2-(3-chlorophenyl)-2-hydroxypropanoic acid Chemical compound OC(=O)C(O)(C)C1=CC=CC(Cl)=C1 MUUPOSALJOLPHK-UHFFFAOYSA-N 0.000 description 1
- BDEPGTDKVXMYQP-UHFFFAOYSA-N 2-(4-benzylpiperazin-1-yl)benzaldehyde Chemical compound O=CC1=CC=CC=C1N1CCN(CC=2C=CC=CC=2)CC1 BDEPGTDKVXMYQP-UHFFFAOYSA-N 0.000 description 1
- ABIQRQZJDCTQFL-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-hydroxypropanenitrile Chemical compound N#CC(O)(C)C1=CC=C(Cl)C=C1 ABIQRQZJDCTQFL-UHFFFAOYSA-N 0.000 description 1
- CUDDZZCNPJYPBF-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-hydroxypropanoic acid Chemical compound OC(=O)C(O)(C)C1=CC=C(Cl)C=C1 CUDDZZCNPJYPBF-UHFFFAOYSA-N 0.000 description 1
- HGEFUOVHKMMCLS-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-hydroxypropanamide Chemical compound CC1=CC=C(C)C(N2CCN(CCCNC(=O)C(C)(O)C=3C=CC(Cl)=CC=3)CC2)=C1 HGEFUOVHKMMCLS-UHFFFAOYSA-N 0.000 description 1
- HOBFSNNENNQQIU-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)C1=CC=CC=C1 HOBFSNNENNQQIU-UHFFFAOYSA-N 0.000 description 1
- LIZVXGBYTGTTTI-UHFFFAOYSA-N 2-[(4-methylphenyl)sulfonylamino]-2-phenylacetic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C(O)=O)C1=CC=CC=C1 LIZVXGBYTGTTTI-UHFFFAOYSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- APSMUYYLXZULMS-UHFFFAOYSA-N 2-bromonaphthalene Chemical compound C1=CC=CC2=CC(Br)=CC=C21 APSMUYYLXZULMS-UHFFFAOYSA-N 0.000 description 1
- AAJLPPDFIRPBDA-UHFFFAOYSA-N 2-cyclohexyl-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C1CCCCC1 AAJLPPDFIRPBDA-UHFFFAOYSA-N 0.000 description 1
- PYXQBGGQMBEYLO-UHFFFAOYSA-N 2-ethyl-2-phenylbutanoic acid Chemical compound CCC(CC)(C(O)=O)C1=CC=CC=C1 PYXQBGGQMBEYLO-UHFFFAOYSA-N 0.000 description 1
- NGHYFCDORXGZOD-UHFFFAOYSA-N 2-ethylsulfanyl-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(C(O)=O)(SCC)C1=CC=CC=C1 NGHYFCDORXGZOD-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- BBVNRWJWEXHHRE-UHFFFAOYSA-N 2-hydroxy-2-(3-phenylphenyl)propanoic acid Chemical compound OC(=O)C(O)(C)C1=CC=CC(C=2C=CC=CC=2)=C1 BBVNRWJWEXHHRE-UHFFFAOYSA-N 0.000 description 1
- GLZYBYUIBZZEPT-UHFFFAOYSA-N 2-hydroxy-2-(4-methoxyphenyl)propanoic acid Chemical compound COC1=CC=C(C(C)(O)C(O)=O)C=C1 GLZYBYUIBZZEPT-UHFFFAOYSA-N 0.000 description 1
- LXGWCXBGZLLXHZ-UHFFFAOYSA-N 2-hydroxy-2-(4-methylphenyl)propanoic acid Chemical compound CC1=CC=C(C(C)(O)C(O)=O)C=C1 LXGWCXBGZLLXHZ-UHFFFAOYSA-N 0.000 description 1
- KUJHPYMDWIIJDD-UHFFFAOYSA-N 2-hydroxy-2-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(O)(C(O)=O)C)=CC=C21 KUJHPYMDWIIJDD-UHFFFAOYSA-N 0.000 description 1
- QYCBZFRDGXIZIP-UHFFFAOYSA-N 2-hydroxy-2-phenylbutanoic acid Chemical compound CCC(O)(C(O)=O)C1=CC=CC=C1 QYCBZFRDGXIZIP-UHFFFAOYSA-N 0.000 description 1
- QOIYLYAWKCQRCJ-UHFFFAOYSA-N 2-hydroxy-n-(3-hydroxypropyl)-2,2-diphenylacetamide Chemical compound C=1C=CC=CC=1C(O)(C(=O)NCCCO)C1=CC=CC=C1 QOIYLYAWKCQRCJ-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- FRICBZWJFIRJOB-UHFFFAOYSA-N 2-piperazin-1-ylbenzonitrile Chemical compound N#CC1=CC=CC=C1N1CCNCC1 FRICBZWJFIRJOB-UHFFFAOYSA-N 0.000 description 1
- FIYRYFJJNWITRF-UHFFFAOYSA-N 3-(6-hydroxy-4-methoxy-6-methylcyclohexa-2,4-dien-1-yl)propanoic acid Chemical compound COC1=CC(C)(O)C(CCC(O)=O)C=C1 FIYRYFJJNWITRF-UHFFFAOYSA-N 0.000 description 1
- NMGODFWGUBLTTA-UHFFFAOYSA-N 3-amino-1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(N)C(=O)NC2=C1 NMGODFWGUBLTTA-UHFFFAOYSA-N 0.000 description 1
- RDKPEKUJILTPNU-UHFFFAOYSA-N 3-ethoxy-2-methyl-3-oxo-2-phenylpropanoic acid Chemical compound CCOC(=O)C(C)(C(O)=O)C1=CC=CC=C1 RDKPEKUJILTPNU-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- CFPZDVAZISWERM-UHFFFAOYSA-N 4-bromo-1,2-dichlorobenzene Chemical compound ClC1=CC=C(Br)C=C1Cl CFPZDVAZISWERM-UHFFFAOYSA-N 0.000 description 1
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- IFTDZNGFPKCUBC-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.CC1=C(C=C(C=C1)C)N1CCN(CC1)CCCNC(C(C1=CC=CC=C1)C(=O)NCC1=CC=CC=C1)=O Chemical compound C(\C=C\C(=O)O)(=O)O.CC1=C(C=C(C=C1)C)N1CCN(CC1)CCCNC(C(C1=CC=CC=C1)C(=O)NCC1=CC=CC=C1)=O IFTDZNGFPKCUBC-WLHGVMLRSA-N 0.000 description 1
- IBVRRWPTRSULQE-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.ClC=1C=C(C=CC1Cl)C(C(=O)NCCCN1CCN(CC1)C1=C(C=CC(=C1)C)C)(C)O Chemical compound C(\C=C\C(=O)O)(=O)O.ClC=1C=C(C=CC1Cl)C(C(=O)NCCCN1CCN(CC1)C1=C(C=CC(=C1)C)C)(C)O IBVRRWPTRSULQE-WLHGVMLRSA-N 0.000 description 1
- PDWVMHPCXOCSKO-WLHGVMLRSA-N C(\C=C\C(=O)O)(=O)O.OC(CC)C1=C(C=CC=C1)N1CCN(CC1)CCCNC(C(C1=CC=CC=C1)C1=CC=CC=C1)=O Chemical compound C(\C=C\C(=O)O)(=O)O.OC(CC)C1=C(C=CC=C1)N1CCN(CC1)CCCNC(C(C1=CC=CC=C1)C1=CC=CC=C1)=O PDWVMHPCXOCSKO-WLHGVMLRSA-N 0.000 description 1
- OWIVRCYYYOTTLR-UHFFFAOYSA-N C1=CC=CC=C1.C1(=CC=CC=C1)CC(=O)N Chemical compound C1=CC=CC=C1.C1(=CC=CC=C1)CC(=O)N OWIVRCYYYOTTLR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- POZQOZTYMQODJG-UHFFFAOYSA-N Cl.Cl.OC(C(=O)NCCCN1CCN(CC1)C1=CC(=CC=C1)C)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound Cl.Cl.OC(C(=O)NCCCN1CCN(CC1)C1=CC(=CC=C1)C)(C1=CC=CC=C1)C1=CC=CC=C1 POZQOZTYMQODJG-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical group FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- GXAMYUGOODKVRM-UHFFFAOYSA-N Flurecol Chemical compound C1=CC=C2C(C(=O)O)(O)C3=CC=CC=C3C2=C1 GXAMYUGOODKVRM-UHFFFAOYSA-N 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000004971 IR microspectroscopy Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- VSBFNCXKYIEYIS-UHFFFAOYSA-N Xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C3=CC=CC=C3OC2=C1 VSBFNCXKYIEYIS-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical compound OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- NWCHELUCVWSRRS-UHFFFAOYSA-N atrolactic acid Chemical compound OC(=O)C(O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- AJEGULYWGRPSOT-UHFFFAOYSA-N benzyl 3-(benzylamino)-3-oxo-2-phenylpropanoate Chemical compound C1(=CC=CC=C1)C(C(=O)OCC1=CC=CC=C1)C(=O)NCC1=CC=CC=C1 AJEGULYWGRPSOT-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940047583 cetamide Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RKIUEYVATKWXKE-UHFFFAOYSA-N chloro 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCl)C=C1 RKIUEYVATKWXKE-UHFFFAOYSA-N 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 229910001916 chloryl Inorganic materials 0.000 description 1
- 125000000622 chloryl group Chemical group O=Cl(=O)[*] 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FGYDHYCFHBSNPE-UHFFFAOYSA-N diethyl phenylmalonate Chemical compound CCOC(=O)C(C(=O)OCC)C1=CC=CC=C1 FGYDHYCFHBSNPE-UHFFFAOYSA-N 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004597 dihydrobenzothiopyranyl group Chemical group S1C(CCC2=C1C=CC=C2)* 0.000 description 1
- WOKPSXJEBSRSAT-UHFFFAOYSA-N dihydrobenzothiopyranyl sulfone group Chemical group S1C(CCC2=C1C=CC=C2)S(=O)(=O)C2SC1=C(CC2)C=CC=C1 WOKPSXJEBSRSAT-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 125000006437 ethyl cyclopropyl group Chemical group 0.000 description 1
- 229940117360 ethyl pyruvate Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000012060 immune response imaging Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- OYUNHEBTDBUMPM-UHFFFAOYSA-N n-[3-[4-(2,3-dimethylphenyl)piperazin-1-yl]propyl]-2-hydroxy-2,2-diphenylacetamide Chemical compound CC1=CC=CC(N2CCN(CCCNC(=O)C(O)(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1C OYUNHEBTDBUMPM-UHFFFAOYSA-N 0.000 description 1
- SWTQCOACAJXQKQ-UHFFFAOYSA-N n-[3-[4-(2,4-dimethylphenyl)piperazin-1-yl]propyl]-2-hydroxy-2,2-diphenylacetamide Chemical compound CC1=CC(C)=CC=C1N1CCN(CCCNC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 SWTQCOACAJXQKQ-UHFFFAOYSA-N 0.000 description 1
- FXVFWICTPRCMIG-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2,2-diphenylacetamide Chemical compound CC1=CC=C(C)C(N2CCN(CCCNC(=O)C(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 FXVFWICTPRCMIG-UHFFFAOYSA-N 0.000 description 1
- IWHVMWPGQYIXKF-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2,2-diphenylpropanamide Chemical compound CC1=CC=C(C)C(N2CCN(CCCNC(=O)C(C)(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 IWHVMWPGQYIXKF-UHFFFAOYSA-N 0.000 description 1
- BTCXIYGPYGWWLD-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-(methanesulfonamido)-2-phenylacetamide Chemical compound CC1=CC=C(C)C(N2CCN(CCCNC(=O)C(NS(C)(=O)=O)C=3C=CC=CC=3)CC2)=C1 BTCXIYGPYGWWLD-UHFFFAOYSA-N 0.000 description 1
- XRHRQOOOJOSPHM-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-[(4-methylphenyl)sulfonylamino]-2-phenylacetamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C=1C=CC=CC=1)C(=O)NCCCN1CCN(C=2C(=CC=C(C)C=2)C)CC1 XRHRQOOOJOSPHM-UHFFFAOYSA-N 0.000 description 1
- AISNMLXRDIFDKI-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-ethyl-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)(CC)C(=O)NCCCN(CC1)CCN1C1=CC(C)=CC=C1C AISNMLXRDIFDKI-UHFFFAOYSA-N 0.000 description 1
- USQZYPGBAZMFIC-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-ethylsulfanyl-2,2-diphenylacetamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SCC)C(=O)NCCCN(CC1)CCN1C1=CC(C)=CC=C1C USQZYPGBAZMFIC-UHFFFAOYSA-N 0.000 description 1
- GIOAFTBXDIKRQM-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-hydroxy-2,2-diphenylacetamide Chemical compound CC1=CC=C(C)C(N2CCN(CCCNC(=O)C(O)(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 GIOAFTBXDIKRQM-UHFFFAOYSA-N 0.000 description 1
- DHDJLGBRNPREQJ-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-hydroxy-2-(4-methoxyphenyl)propanamide Chemical compound C1=CC(OC)=CC=C1C(C)(O)C(=O)NCCCN1CCN(C=2C(=CC=C(C)C=2)C)CC1 DHDJLGBRNPREQJ-UHFFFAOYSA-N 0.000 description 1
- DGNAIPMTYFLRGY-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-methoxy-2,2-diphenylacetamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC)C(=O)NCCCN(CC1)CCN1C1=CC(C)=CC=C1C DGNAIPMTYFLRGY-UHFFFAOYSA-N 0.000 description 1
- IYLMSISFRQNLRQ-UHFFFAOYSA-N n-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-phenyl-2-[(2-phenylacetyl)amino]acetamide Chemical compound CC1=CC=C(C)C(N2CCN(CCCNC(=O)C(NC(=O)CC=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 IYLMSISFRQNLRQ-UHFFFAOYSA-N 0.000 description 1
- KDHYTNLSAFKNOW-UHFFFAOYSA-N n-[3-[4-(2,6-dimethylphenyl)piperazin-1-yl]propyl]-2-hydroxy-2,2-diphenylacetamide Chemical compound CC1=CC=CC(C)=C1N1CCN(CCCNC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 KDHYTNLSAFKNOW-UHFFFAOYSA-N 0.000 description 1
- NOKALEVDWITADT-UHFFFAOYSA-N n-benzyl-n'-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propyl]-2-methyl-2-phenylpropanediamide Chemical compound CC1=CC=C(C)C(N2CCN(CCCNC(=O)C(C)(C(=O)NCC=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 NOKALEVDWITADT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- SRQUCXWSPYRKJJ-UHFFFAOYSA-N tert-butyl n-[2-[3-[4-(2,5-dimethylphenyl)piperazin-1-yl]propylamino]-2-oxo-1-phenylethyl]carbamate Chemical compound CC1=CC=C(C)C(N2CCN(CCCNC(=O)C(NC(=O)OC(C)(C)C)C=3C=CC=CC=3)CC2)=C1 SRQUCXWSPYRKJJ-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004589 thienofuryl group Chemical group O1C(=CC2=C1C=CS2)* 0.000 description 1
- 125000004587 thienothienyl group Chemical group S1C(=CC2=C1C=CS2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 1
- JACRWUWPXAESPB-UHFFFAOYSA-N tropic acid Chemical compound OCC(C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式I: [式中、R1は水素、低級アルキル又はアリール−低級アルキルを表す; R2は水素、低級アルキル、OR6、S(O)mR6(mは0、1又は2である)、 NHS(O)nR6(nは1又は2である)、OC(O)R6、C(O)NR6R7、NR6R7又はN(R7)C(O)R6 を表す; R3とR4の各々は、相互に独立して、水素を表すか又は置換されているか又は 置換されていない下記の基:即ち、低級アルキル、シクロアルキル、アリール、 アリール−低級アルキル、ヘテロサイクル又はヘテロサイクル−低級アルキル( ここで、置換基は低級アルキル、ハロゲン、OR6、SR6、NR6R7、CN、NO2、CF3、 ヘテロサイクル又はアリールである)の一つを表すか、又は、R3とR4は、これ らが結合している炭素原子と共に、置換(即ち、1〜4個の位置が置換されてい る)又は非置換アリール又はヘテロサイクル(ここで、置換基は低級アルキル、 OH又はヒドロキシル低級アルキルである)を形成している; R5は置換又は非置換アリール(ここで、置換基は低級アルキル、シクロアル キル、ヒドロキシ−低級アルキル、ヒドロキシ−シクロアルキル、アルコキシ− 低級アルキル、アルコキシ−シクロアルキル、ハロゲン、OR6、SR6、NR6R7又はC Nである)を表す; R6とR7の各々は、相互に独立して、水素を表すか又は置換されているか又は 置換されていない下記の基:即ち、低級アルキル、アリール又はアリール−低級 アルキル(ここで、置換基は低級アルキル、ハロゲン又は低級アルコキシである )の一つを表す;但し、R3又はR4が水素を表す場合には、R2はOHを表わさな いものとする]で表わされる化合物又はその製剤学的に許容される塩の一つ。 2.R1が水素又は低級アルキルを表す、請求項1に記載の式(I)の化合物又は その製剤学的に許容される塩の一つ。 3.R2が水素、低級アルキル、OR6(ここでR6は水素又はアリール−低級アル キルを表す)、SR6(ここでR6は低級アルキルを表す)、NH2、NHSO2R6(ここでR6 は低級アルキル又はアリール−低級アルキルを表す)、OC(O)R6(ここでR6はア リール−低級アルキルを表す)、C(O)NR6R7又はN(R7)C(O)R6(ここでR7は水素を 表し、R6はアリール−低級アルキルを表す)を表す、請求項2に記載の化合物又 はその製剤学的に許容される塩の一つ。 4.R5が置換又は非置換フェニルを表し、この場合、置換基は低級アルキル、 CN,ハロゲン、ヒドロキシ−低級アルキル、ヒドロキシ−シクロアルキル、低級 アルコキシ−低級アルキル又はOR6(R6は低級アルキルである)である、請求項 3に記載の化合物又はその製剤学的に許容される塩の一つ。 5.R3とR4の各々は、相互に独立して、水素を表すか又は置換されているか 又は置換されていない下記の基:即ち、低級アルキル、シクロアルキル又はアリ ールの一つを表し、この場合、置換基はハロゲン、OR6(R6は低級アルキルであ る)又はアリールである、請求項4に記載の化合物又はその製剤学的に許容され る塩の一つ。 6.R1が水素を表し、R5が2,5-ジメチルフェニルを表す、請求項5に記載の 化合物又はその製剤学的に許容される塩の一つ。 7.RがOR6(R6は水素、低級アルキル又はアリール−低級アルキルを表す) を表す、請求項6に記載の化合物又はその製剤学的に許容される塩の一つ。 8.R3が低級アルキルを表し、R4がフェニルを表す、請求項6に記載の化合 物又はその製剤学的に許容される塩の一つ。 9.R3とR4が、これらが結合している炭素原子と共に、置換又は非置換アリ ール又はヘテロサイクルを形成している、請求項4に記載の化合物又はその製剤 学的に許容される塩の一つ。 10.R1が水素を表し、R5が2-メトキシフェニル又は2,5-ジメチルフェニルを 表す、請求項9に記載の化合物又はその製剤学的に許容される塩の一つ。 11.R2がOR6(ここでR6は水素、低級アルキル又はアリール−低級アルキル を表す)を表す、請求項10に記載の化合物又はその製剤学的に許容される塩の一 つ。 12.R3とR4が、これらが結合している炭素原子と共に、9-キサンテニル-9- フルオレニルを形成している、請求項11に記載の化合物又はその製剤学的に許容 される塩の一つ。 13.下記の式に相当する対応する、請求項1に記載の化合物又はその製剤学的 に許容される塩の一つ: 14.下記の式: に相当する、請求項1に記載の化合物又はその製剤学的に許容される塩の一つ。 15.式Ia:[式中、式中、R1は水素、低級アルキル又はアリール−低級アルキルを表す; R2は水素、低級アルキル、OR6、S(O)mR6(mは0、1又は2である)、 NHS(O)nR6(nは1又は2である)、OC(O)R6、C(O)NR6R7、NR6R7又はN(R7)C(O)R6 を表す; R3とR4の各々は、相互に独立して、水素を表すか又は置換されているか又は 置換されていない下記の基:即ち、低級アルキル、シクロアルキル、アリール、 アリール−低級アルキル、ヘテロサイクル又はヘテロサイクル−低級アルキル( ここで、置換基は低級アルキル、ハロゲン、OR6、SR6、NR6R7、CN、NO2、CF3、 ヘテロサイクル又はアリールである)の一つを表すか、又は、R3とR4は、これ らが結合している炭素原子と共に、置換又は非置換アリール又はヘテロサイクル (ここで、置換基は低級アルキル、OH又はヒドロキシル低級アルキルである)を 形成している; R5は置換又は非置換アリール(ここで、置換基は低級アルキル、シクロアル キル、ヒドロキシ−低級アルキル、ヒドロキシ−シクロアルキル、アルコキシ− 低級アルキル、アルコキシ−シクロアルキル、ハロゲン、OR6、SR6、NR6R7又はC Nである)を表す; R6とR7の各々は、相互に独立して、水素を表すか又は置換されているか又 は置換されていない下記の基:即ち、低級アルキル、アリール又はアリール−低 級アルキル(ここで、置換基は低級アルキル、ハロゲン又は低級アルコキシであ る)の一つを表す]で表わされる化合物又はその製剤学的に許容される塩の一つ を含有する医薬組成物。 16.R1が水素を表し、R5が2,5-ジメチルフェニルを表す、請求項15に記載の 医薬組成物。 17.R2がOR6(R6は水素、低級アルキル又はアリール−低級アルキルを表す) を表し、R3が低級アルキルを表し、R4がフェニルを表す、請求項16に記載の医 薬組成物。 18.前記化合物が、式: に相当する、請求項17に記載の医薬組成物。 19.前立腺の良性増殖症処置用の医薬を調製するための、請求項15に記載の式 Iaの化合物の使用。 20.医薬を調製するための、請求項16〜18のいずれかに記載の式Iaの化合物の 使用。 21.門脈圧高進症処置用の医薬を調製するための、請求項15に記載の式Iaの化 合物の使用。 22。門脈圧高進症処置用の医薬を調製するための、請求項16〜18のいずれかに 記載の式Iaの化合物の使用。 23.硬変症処置用の医薬を調製するための、請求項15に記載の式Iaの化合物の 使用。 24.請求項15に記載の医薬組成物を投与することからなる、前立腺の良性増殖 症の処置方法。 25.請求項16に記載の医薬組成物を前記患者に投与することからなる、請求 項24に記載の方法。 26.請求項17に記載の医薬組成物を前記患者に投与することからなる、請求項 24に記載の方法。 27.請求項18に記載の医薬組成物を前記患者に投与することからなる、請求項 24に記載の方法。 28.ラットの門脈の収縮の抑制についてのKbであって、ラットの大動脈の収 縮の抑制についてのKbより少なくとも5倍低いKbを有する化合物を治療に有効 な量、投与することからなり、そして、上記化合物を少なくとも1μMのKiを有 するα1-交感神経受容体に連結させる、門脈圧高進症の処置方法。 29.前記化合物は、ラットの門脈の収縮の抑制についてのKbであって、ラッ トの大動脈の収縮の抑制についてのKbより少なくとも20倍低いKbを有する、請 求項28に記載の方法。 30.前記化合物は、更に、ウサギの門脈の収縮の抑制についてのKbであって 、ウサギの大動脈の収縮の抑制についてのKbより少なくとも5倍低いKbを有す る、請求項28に記載の方法。 31.前記化合物は、ウサギの門脈の収縮の抑制についてのKbであって、ウサ ギの大動脈の収縮の抑制についてのKbより少なくとも20倍低いKbを有する、請 求項29に記載の方法。 32.前記化合物は、ウサギの門脈の収縮の抑制についてのKbであって、ウサ ギの伏在静脈の収縮の抑制についてのKbより少なくとも2倍低いKbも有する、 請求項28に記載の方法。 33.式: の化合物を投与するとからなる、請求項28に記載の方法。 34.ウサギの門脈の収縮の抑制についてのKbであって、ウサギの大動脈の収 縮の抑制についてのKbより少なくとも5倍低いKbを有する化合物を治療に有効 な量、投与することからなり、そして、上記化合物を少なくとも1μMのKiを有 するα1-交感神経受容体に連結させる、門脈圧高進症の処置方法。 35.前記化合物は、ウサギの門脈の収縮の抑制についてのKbであって、ウサ ギの大動脈の収縮の抑制についてのKbより少なくとも20倍低いKbを有する、請 求項34に記載の方法。 36.前記化合物は、更に、ウサギの門脈の収縮の抑制についてのKbであって 、ウサギの伏在静脈の収縮の抑制についてのKbより少なくとも2倍低いKbも有 する、請求項35に記載の方法。 37.ウサギの門脈の収縮の抑制についてのKbであって、ウサギの伏在静脈の 収縮の抑制についてのKbより少なくとも2倍低いKbを有する化合物を治療に有 効な量、投与することからなり、そして、上記化合物を少なくとも1μMのKiを 有するα1-交感神経受容体に連結させる、門脈圧高進症の処置方法。 38.式IM: [式中、Wは窒素又は炭素原子を表し; R1は水素、低級アルキル、アリール−低級アルキル、CN、CO2R9、CON(R9)2、 シクロアルキル又は(CH2)pCO2R9を表す; R’2は水素、低級アルキル、OR6、S(O)mR6(mは0、1又は2である)、 NHS(O)nR6(は1又は2である)、OC(O)R6、C(O)NR6R7、NR6R7、N(R7)C(O)R6、C O2R10、(CH2)pCO2R10、OR12、N-R12-R13、(CH2)pCN(R10)2を表すか、又はCR’2 はシクロプロピル環を形成しており、そしてR’3とR’4の一方は存在しない; R’3とR’4の各々は、相互に独立して、水素を表すか又は置換されているか 又は置換されていない下記の基:即ち、低級アルキル又はアルコキシ、シクロア ルキル、アリール、アリール−低級アルキル、ヘテロサイクル、ヘテロサイクル −低級アルキル又はNR'10R''10(ここで、置換基は、場合により1個又はそれ以 上のハロゲン原子によって置換されている低級アルキル、ハロゲン、OR6、 SR6、NR6R7、CN、NO2、ヘテロサイクル、アリール又は2個の隣接する炭素原子 上のメチレンジオキシである)の一つを表すか、又はR’3とR’4は、これらが 結合している炭素原子と共に、置換又は非置換アリール又はヘテロサイクル(こ こで、置換基は低級アルキル、OH又はヒドロキシル低級アルキルである)を形成 している; R’5は置換又は非置換低級アルキル、アリール又はヘテロサイクル(ここで 、置換基は、場合により1個又はそれ以上のハロゲン原子によって置換されてい る低級アルキル、シクロアルキル、ヒドロキシ−低級アルキル、ヒドロキシ−シ クロアルキル、アルコキシ−低級アルキル、アルコキシ−シクロアルキル、ハロ ゲン、2個の隣接する炭素原子上のメチレンジオキシ、OR6、SR6、NR6R7、CN、C O2R10、(CH2)pCON(R10)2又は(CH2)pCOR10である)を表す; R6とR7の各々は、相互に独立して、水素を表すか又は置換されているか又は 置換されていない下記の基:即ち、低級アルキル、アリール又はアリール−低級 アルキル(この場合、置換基は低級アルキル、ハロゲン又は低級アルコキシであ る)の一つを表す; R8は水素、シアノ、CO2R9、CON(R9)2又はアリールから選ばれる;但し、Wが 窒素原子である場合は、R8は存在しない; R9、R10、R’10、R’’10及びR11の各々は、相互に独立して、水素、 低級アルキル又はシクロアルキルを表し、このアルキル及びシクロアルキル基は 、場合により1個又はそれ以上のハロゲンで置換されている; R12とR13の各々は、相互に独立して、水素、置換又は非置換低級アルキル又 はシクロアルキル、CHO、COR10、CONR10R11又は(CH2)pOR10を表す; はCOから選ばれる; qは0〜3の整数である; pは0〜3の整数である; Xは酸素、硫黄又はNR14(R14は水素、シアノ又はSO2R10である)から選ばれ る; R15は水素又はヒドロキシである;但し、n=p=0の場合には、Vは CH2OR10ではないものとする]の化合物又はその製剤学的に許容される塩の一つを 治療に有効な量、投与することからなる門脈圧高進症の処置方法。 39.請求項38に記載の式IMの化合物を治療に有効な量、投与することからな る硬変症の処置方法。 40.門脈圧高進症処置用の医薬を調製するための、請求項38に記載の式IMの化 合物の使用。 41.硬変症処置用の医薬を調製するための、請求項38に記載の式IMの化合物の 使用。 42.式IN: [式中、R’5、R9及びR10は請求項38に記載の意義を有する;Zは CHR18又はNHR9基を表す;Rxは基: (式中、R19は水素原子又は塩素原子を表す)から選ばれる;Tは-NH-(CH2)3 テロサイクル、CONR9R10、CO2R9及びSO2R9から選ばれる]の化合物を治療に有効 な量、投与することからなる門脈圧高進症の処置方法。 43.門脈圧高進症又は硬変症処置用の医薬を調製するための、請求項42に記載 の式INの化合物の使用。 44.式IR:[式中、R20はアセチルアミノ、アミノ、シアノ、トリフルオロアセチルアミノ 、ハロゲン、水素、ヒドロキシ、ニトロ、メチルスルホニルアミノ、2-プロピニ ルオキシ又は1〜3個のハロゲン原子で置換されているか又は置換されていない 下記の基:即ち、低級アルキル、低級シクロアルキル、シクロアルキル−低級ア ルキル、低級アルコキシ、シクロアルキルオキシ、シクロアルキル−低級アルコ キシ又は低級アルキルチオの一つ、又は、下記の基:即ち、アリール、アリール −アルキル、ヘテロサイクル、ヘテロサイクル−低級アルキル、アリールオキシ 、アリール−低級アルコキシ、ヘテロサイクル−オキシ又はヘテロサイクル−低 級アルコキシ(上記アリール基又はヘテロサイクルは、場合により、ハロゲン原 子及びシアノ基から選ばれた1個又は2個の別々の基により置換されている)の 一つを表す; R21はCN、ハロゲン、水素又はヒドロキシを表すか、又は、場合により1〜3 個のハロゲン原子で置換されている下記の基:即ち、低級アルキル又は低級アル コキシの一つを表す; R22及びR23は、独立して、水素又はメチルを表わすか、又は一緒にエチレン を表わす; R24は下記の式IRa、IRb、IRc及びIRd: (式中、X1はC(O)、CH2又はCH(OH)を表し;Y1はCH2又はCH(OH)を表し;Z1はN 又はC(R29)(R29は水素、低級アルキル又はヒドロキシを表す)を表す)の化合物 の一つを表す; R25は水素を表すか、又は、場合により1〜3個のハロゲン原子で置換されて いる下記の基:即ち、低級アルキル、シクロアルキル、シクロアルキル−低級ア ルキルの一つを表すか、又は、下記の基:即ち、アリール、ヘテロサイクル、ア リール−低級アルキル又はヘテロサイクリル一低級アルキル(上記アリール基又 はヘテロサイクルは、場合により、ハロゲン原子、シアノ、低級アルコキシ、低 級アルキル又はアリールから選ばれた1〜3個の基により置換されている)の一 つを表す; R26はR30C(O)-、カルバモイル、シアノ、ジ(低級アルキル)アミノ、ハロ ゲン、水素、ヒドロキシ、ヒドロキシイミノメチル、R30S、R30SO2をわ表すか、 又は、ハロゲン、ヒドロキシ又は低級アルコキシから選ばれた1〜3個の基によ り置換されているか又は置換されていない下記の基:即ち、低級アルキル、シク ロアルキル、低級アルコキシ又は低級アルコキシ−低級アルキルの一つを表わす か、又は、下記の基:即ち、アリール、ヘテロサイクル、アリール−低級アルキ ル又はヘテロサイクル−低級アルキル(上記アリール基又はヘテロサイクルは、 場合により、ハロゲン、シアノ、低級アルコキシ、低級アルキル又はアリールか ら選ばれた1〜3個の基により置換されている)の一つを表すか、又はR26とR2 9 は一緒に-CH2-(CH2)2-CH2-基を形成している; R27とR28は、独立して、水素、ヒドロキシ、メチル又はエチルを表す; R30は低級アルキルを表す]の化合物又はその製剤学的に許容される塩又はN- オキシドの一つを、治療に有効な量、投与することからなる門脈圧高進症の処置 方法。 45.門脈圧高進症又は硬変症処置用の医薬を調製するための、請求項44に記載 の式IRの化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62827696A | 1996-04-05 | 1996-04-05 | |
US08/628,276 | 1996-04-05 | ||
PCT/FR1997/000615 WO1997037983A1 (fr) | 1996-04-05 | 1997-04-04 | ANTAGONISTES DU RECEPTEUR α1-ADRENERGIQUE |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000508310A true JP2000508310A (ja) | 2000-07-04 |
JP3845452B2 JP3845452B2 (ja) | 2006-11-15 |
Family
ID=24518205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53591997A Expired - Fee Related JP3845452B2 (ja) | 1996-04-05 | 1997-04-04 | α1―交感神経受容体拮抗薬 |
Country Status (15)
Country | Link |
---|---|
US (1) | US6300499B1 (ja) |
EP (1) | EP0891344B1 (ja) |
JP (1) | JP3845452B2 (ja) |
AT (1) | ATE229946T1 (ja) |
AU (1) | AU2393997A (ja) |
CZ (1) | CZ315098A3 (ja) |
DE (1) | DE69717978T2 (ja) |
DK (1) | DK0891344T3 (ja) |
ES (1) | ES2188936T3 (ja) |
HU (1) | HUP9901680A3 (ja) |
IL (1) | IL126411A0 (ja) |
NO (1) | NO984631L (ja) |
PL (1) | PL329190A1 (ja) |
RU (1) | RU2179554C2 (ja) |
WO (1) | WO1997037983A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005538974A (ja) * | 2002-07-04 | 2005-12-22 | シュバルツ ファルマ アクチェンゲゼルシャフト | 中枢神経系の病気を治療するドーパミン−d3リガンドとして使用するためのヘテロアレーンカルボキサミド |
JP2006508090A (ja) * | 2002-10-31 | 2006-03-09 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規β−アゴニスト、それらの製造方法及び医薬組成物としてのそれらの使用 |
JP2014526458A (ja) * | 2011-09-12 | 2014-10-06 | カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ | アリール化β−ジカルボニル化合物とその製造方法 |
WO2015029447A1 (ja) * | 2013-08-30 | 2015-03-05 | 興和株式会社 | 光学活性カルビノール化合物の製造方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5661163A (en) * | 1995-06-07 | 1997-08-26 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
GB9819860D0 (en) | 1998-09-12 | 1998-11-04 | Zeneca Ltd | Chemical compounds |
AU2002251409A1 (en) * | 2002-04-08 | 2003-10-20 | Ranbaxy Laboratories Limited | Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers |
WO2006021344A1 (en) * | 2004-08-27 | 2006-03-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with alpha-1a adrenergic receptor (adra1a) |
CN103288745A (zh) * | 2013-06-25 | 2013-09-11 | 南方医科大学 | 一种2,6-二取代哒嗪酮类化合物及其应用 |
CN103304486A (zh) * | 2013-06-25 | 2013-09-18 | 南方医科大学 | 6-(4-芳基哌嗪-1-基)哒嗪-3(2h)-酮及其应用 |
CN115124415A (zh) * | 2022-06-20 | 2022-09-30 | 西咸新区行易先进材料科技有限公司 | 一种合成阿卓乳酸的催化反应方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2722529A (en) * | 1955-11-01 | Amides of certain l-amevoalkyl-x-phenyl | ||
US2833770A (en) * | 1958-05-06 | Chj-chj | ||
NL8005133A (nl) * | 1980-09-12 | 1982-04-01 | Duphar Int Res | Fenylpiperazinederivaten met antiagressieve werking. |
CA1340113C (en) | 1988-05-24 | 1998-11-03 | Magid A. Abou-Gharbia | Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity |
DE69033393T2 (de) | 1989-04-22 | 2000-05-25 | Wyeth John & Brother Ltd | Tertiäre alkyl funktionalisierte Piperazin-Derivate |
FR2655988B1 (fr) * | 1989-12-20 | 1994-05-20 | Adir Cie | Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
DE4121276C2 (de) | 1991-06-27 | 1994-02-17 | Metallgesellschaft Ag | Verfahren zur Herstellung sulfathaltiger, basischer Polyaluminiumchlorid-Lösungen |
GB9200293D0 (en) | 1992-01-08 | 1992-02-26 | Wyeth John & Brother Ltd | Piperazine derivatives |
SE9201138D0 (sv) * | 1992-04-09 | 1992-04-09 | Astra Ab | Novel phthalimidoalkylpiperazines |
US5284990A (en) | 1992-07-16 | 1994-02-08 | Stratco, Inc. | Method for converting a hydrogen fluoride alkylation unit to a sulfuric acid alkylation unit |
US5349844A (en) | 1992-09-11 | 1994-09-27 | Trc Companies, Inc. | System and method for resonant filter mass monitoring |
SE9300295D0 (sv) | 1993-01-28 | 1993-01-28 | Benny Carlstroem | Foerfarande och anordning foer bindning av tandlagningsmaterial |
US6087346A (en) * | 1993-06-23 | 2000-07-11 | Cambridge Neuroscience, Inc. | Sigma receptor ligands and the use thereof |
US5414585A (en) | 1993-07-19 | 1995-05-09 | Quantum Corp. | Rotating tape edge guide |
IT1266582B1 (it) * | 1993-07-30 | 1997-01-09 | Recordati Chem Pharm | Derivati (di)azacicloesanici e diazacicloeptanici |
US5696123A (en) * | 1994-09-17 | 1997-12-09 | Boehringer Ingelheim Kg | Neurokinin antagonists |
-
1997
- 1997-04-04 CZ CZ983150A patent/CZ315098A3/cs unknown
- 1997-04-04 RU RU98119949/04A patent/RU2179554C2/ru not_active IP Right Cessation
- 1997-04-04 PL PL97329190A patent/PL329190A1/xx unknown
- 1997-04-04 DE DE69717978T patent/DE69717978T2/de not_active Expired - Fee Related
- 1997-04-04 IL IL12641197A patent/IL126411A0/xx unknown
- 1997-04-04 AU AU23939/97A patent/AU2393997A/en not_active Abandoned
- 1997-04-04 WO PCT/FR1997/000615 patent/WO1997037983A1/fr not_active Application Discontinuation
- 1997-04-04 EP EP97919488A patent/EP0891344B1/fr not_active Expired - Lifetime
- 1997-04-04 US US09/155,535 patent/US6300499B1/en not_active Expired - Fee Related
- 1997-04-04 ES ES97919488T patent/ES2188936T3/es not_active Expired - Lifetime
- 1997-04-04 JP JP53591997A patent/JP3845452B2/ja not_active Expired - Fee Related
- 1997-04-04 DK DK97919488T patent/DK0891344T3/da active
- 1997-04-04 HU HU9901680A patent/HUP9901680A3/hu unknown
- 1997-04-04 AT AT97919488T patent/ATE229946T1/de not_active IP Right Cessation
-
1998
- 1998-10-02 NO NO984631A patent/NO984631L/no not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005538974A (ja) * | 2002-07-04 | 2005-12-22 | シュバルツ ファルマ アクチェンゲゼルシャフト | 中枢神経系の病気を治療するドーパミン−d3リガンドとして使用するためのヘテロアレーンカルボキサミド |
JP2006508090A (ja) * | 2002-10-31 | 2006-03-09 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規β−アゴニスト、それらの製造方法及び医薬組成物としてのそれらの使用 |
JP2014526458A (ja) * | 2011-09-12 | 2014-10-06 | カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ | アリール化β−ジカルボニル化合物とその製造方法 |
WO2015029447A1 (ja) * | 2013-08-30 | 2015-03-05 | 興和株式会社 | 光学活性カルビノール化合物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2393997A (en) | 1997-10-29 |
RU2179554C2 (ru) | 2002-02-20 |
US6300499B1 (en) | 2001-10-09 |
PL329190A1 (en) | 1999-03-15 |
NO984631D0 (no) | 1998-10-02 |
EP0891344A1 (fr) | 1999-01-20 |
DE69717978T2 (de) | 2003-10-02 |
JP3845452B2 (ja) | 2006-11-15 |
HUP9901680A3 (en) | 2000-12-28 |
NO984631L (no) | 1998-12-02 |
ATE229946T1 (de) | 2003-01-15 |
CZ315098A3 (cs) | 1999-04-14 |
WO1997037983A1 (fr) | 1997-10-16 |
ES2188936T3 (es) | 2003-07-01 |
DK0891344T3 (da) | 2003-04-07 |
HUP9901680A2 (hu) | 1999-09-28 |
EP0891344B1 (fr) | 2002-12-18 |
IL126411A0 (en) | 1999-05-09 |
DE69717978D1 (de) | 2003-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3507494B2 (ja) | タキキニン拮抗薬 | |
US5633376A (en) | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands | |
JP3421323B2 (ja) | ピペリジンccr−3受容体拮抗薬 | |
JP2005526137A (ja) | アミノテトラリン−誘動尿素のバニロイドvr1受容体調節剤 | |
JP2009538358A (ja) | 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター | |
MXPA02007035A (es) | Compuesto ciclico conteniendo nitrogeno y composicion farmaceutica conteniendo el compuesto. | |
BRPI0709803A2 (pt) | moduladores de benzimidazol de vr1 | |
JP2003528096A (ja) | デカヒドロ−イソキノリン | |
WO2002024653A1 (en) | Compounds and methods for modulation of estrogen receptors | |
CN1152016C (zh) | 2-(3,5-二-三氟甲基-苯基)-n-甲基-n-(6-吗啉-4-基-4-邻-甲苯基-吡啶-3-基)-异丁酰胺 | |
JP5937353B2 (ja) | 冷感−メントール受容体拮抗剤 | |
JP2000508310A (ja) | α▲下1▼―交感神経受容体拮抗薬 | |
BRPI1009757B1 (pt) | composto derivado de arilpiperazina útil no tratamento de psicose, esquizofrenia, mania aguda, distúrbio bipolar, distúrbio autista ou depressão, composição farmacêutica, e, uso da mesma | |
JP4076234B2 (ja) | テトラヒドロベンズインドール化合物 | |
JPH0283375A (ja) | 2−置換ピペラジニル−2−(1,2−ベンズイソキサゾール−3−イル)酢酸誘導体 | |
JP2013544894A (ja) | Trpm8モジュレータとしてのイミダゾ[1,2−a]ピリジンスルホンアミド | |
JP2001512727A (ja) | 5ht−1受容体のリガンドとしてのニ環式化合物 | |
EP2261206A1 (en) | Indolinone compound | |
JPH0244306B2 (ja) | ||
JPH11504921A (ja) | ニューロキニンアンタゴニストとしてのピペラジノ誘導体 | |
JPS5955878A (ja) | 新規なフエニルピペラジン誘導体 | |
CN1043574C (zh) | 具有中枢神经系统活性的杂环胺 | |
JP5628937B2 (ja) | 5−ht6受容体リガンドとしてのスルホン化合物 | |
NZ250580A (en) | 3-(hetero)aryloxymorphinan derivatives and their use in the manufacture of medicaments | |
JPH05186460A (ja) | 2−(1−ピペリジル)エタノール誘導体、その製造方法およびその治療への適用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050810 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051013 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060529 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060725 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060821 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090825 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090825 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100825 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |